Research ArticleNipah Virus

A Hendra Virus G Glycoprotein Subunit Vaccine Protects African Green Monkeys from Nipah Virus Challenge

See allHide authors and affiliations

Science Translational Medicine  08 Aug 2012:
Vol. 4, Issue 146, pp. 146ra107
DOI: 10.1126/scitranslmed.3004241
  • Fig. 1

    Schematic diagram of sGHeV vaccination and NiV challenge schedule. Dates of sGHeV vaccination, NiV challenge, and euthanasia are indicated by arrows. Blood and swab specimens were collected on days −42, −7, 0, 3, 5, 7, 10, 14, 21, and 28 after challenge as indicated (*). Gray text denotes challenge timeline; black text denotes vaccination timeline. AGM numbers for subjects in each vaccine dose group and one control subject are shown.

  • Fig. 2

    Survival curve of NiV-infected subjects. Data from control subjects (n = 2) and sGHeV-vaccinated subjects (n = 9) were used to generate the Kaplan-Meier survival curve. Control included data from one additional historical control subject. Vaccinated subjects received 10, 50, or 100 μg of sGHeV administered subcutaneously twice. Average time to end-stage disease was 11 days in control subjects, whereas all vaccinated subjects survived until euthanasia at the end of the study.

  • Fig. 3

    Absence of NiV antigen in sGHeV-vaccinated subjects. Lung, brainstem, and spleen tissue sections were stained with an N protein–specific polyclonal rabbit antibody, and images were obtained at an original magnification of 20×.

  • Fig. 4

    NiV- and HeV-specific Ig in vaccinated subjects. Serum and nasal swabs were collected from vaccinated subjects, and IgG, IgA, and IgM responses were evaluated using sGHeV and sGNiV multiplexed microsphere assays. Sera or swabs from subjects in the same vaccine dose group (n = 3) were assayed individually, and the mean of microsphere MFIs was calculated, which is shown on the y axis. Error bars represent the SEM. Serum sG-specific IgM, IgG, and IgA are shown in black (sGHeV and sGNiV), and mucosal sG-specific IgA is shown in gray (sGHeV and sGNiV).

  • Table 1

    HeV and NiV serum neutralization titers in vaccinated AGMs. Reciprocal serum dilution at which 50% of virus was neutralized.

Additional Files

  • Supplementary Materials for:

    A Hendra Virus G Glycoprotein Subunit Vaccine Protects African Green Monkeys from Nipah Virus Challenge

    Katharine N. Bossart, Barry Rockx, Friederike Feldmann, Doug Brining, Dana Scott, Rachel LaCasse, Joan B. Geisbert, Yan-Ru Feng, Yee-Peng Chan, Andrew C. Hickey, Christopher C. Broder,* Heinz Feldmann, Thomas W. Geisbert

    *To whom correspondence should be addressed. E-mail: christopher.broder{at}usuhs.edu

    Published 8 August 2012, Sci. Transl. Med. 4, 146ra107 (2012)
    DOI: 10.1126/scitranslmed.3004241

    This PDF file includes:

    • Fig. S1. NiV-mediated disease in the control subject.
    • Fig. S2. NiV F–specific IgM in vaccinated subjects.

    [Download PDF]

Stay Connected to Science Translational Medicine

Navigate This Article